Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension.

ABSTRACT:

Rationale and objective

APOL1 risk alleles are associated with increased cardiovascular and chronic kidney disease (CKD) risk. It is unknown whether knowledge of APOL1 risk status motivates patients and providers to attain recommended blood pressure (BP) targets to reduce cardiovascular disease.

Study design

Multicenter, pragmatic, randomized controlled clinical trial.

Setting and participants

6650 individuals with African ancestry and hypertension from 13 health systems.

Intervention

APOL1 genotyping with clinical decision support (CDS) results are returned to participants and providers immediately (intervention) or at 6 months (control). A subset of participants are re-randomized to pharmacogenomic testing for relevant antihypertensive medications (pharmacoge

SUBMITTER: Eadon MT 

PROVIDER: S-EPMC9928488 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature